Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $3

Author: Benzinga Newsdesk | November 03, 2023 02:56pm

RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from $4 to $3.

Posted In: KPTI